Leadership Team

Edward Conner, M.D.

Edward Conner, M.D.

Senior Vice President and CMO

Edward Conner, M.D. has served as Senior Vice President and Chief Medical Officer since November 2016.  He has over 10 years of industry experience in early and late stage clinical development in a broad range of disease areas including rare diseases, oncology and infectious diseases. Prior to joining Sangamo, Dr. Conner served as Vice President, Clinical Sciences at Ultragenyx Pharmaceuticals, a biopharmaceutical company developing novel products for the treatment of rare and ultra-rare diseases. Prior to joining Ultragenyx, he served as Senior Medical Director at BioMarin Pharmaceuticals Inc., where he led protocol development and regulatory interaction for its global phase 3 program in Pompe disease. From 2008 to 2013, Dr. Conner served as Medical Director at Genentech and was the clinical science team leader of two product candidates, including Xolair®, which is now a commercial drug product. He completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology & Allergic Diseases at Johns Hopkins School of Medicine. He received a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco.

Nathalie Dubois-Stringfellow, Ph.D.

Nathalie Dubois-Stringfellow, Ph.D.

Vice President, Product Development and Management

Nathalie Dubois-Stringfellow, Ph.D., has served as Vice President, Product Development and Management since January 2015 and oversees the development and execution of project team strategy for Sangamo’s ZFP therapeutic programs in hemophilia, lysosomal storage disorders, hemoglobinopathies, HIV and Huntington’s disease. She has over 20 years of experience implementing and managing preclinical and clinical development of biologic therapies in oncology, as well as immune, infectious and genetic diseases. Dr. Dubois-Stringfellow joined Sangamo in January 2011 as Senior Director, Project Management. Prior to joining Sangamo, she held various positions in Discovery Research, Preclinical Research, Project Management, Clinical Development, and Portfolio Management at Chiron Corp., Bayer Corp., Signature Biosciences, Inc. and most recently XOMA LLC, where she served as Senior Director, Preclinical Portfolio and Alliance Management. Dr. Dubois-Stringfellow was a post-doctoral fellow at the University of North Carolina, Chapel Hill, where she studied angiogenesis and tumorigenesis in transgenic mice and cell culture systems. She received her M.S. in Genetics and Immunology, and her Ph.D. in Human Genetics from the Université Pierre et Marie Curie in Paris, France.

Heather Erickson

Heather Erickson

Chief of Staff

Heather Erickson has served as Chief of Staff since July 2016 and is responsible for the execution of Sangamo's daily operations and special projects. Prior to joining Sangamo, Ms. Erickson served as the President and CEO of the Life Sciences Foundation, a national research and education foundation focused on collecting and organizing the story of biotechnology and providing audiences with context for the role the life sciences play in society. From 2004 to 2012, Ms. Erickson founded and served as President of the MedTech Association, leading the industry trade organization to become the hub of Upstate New York’s bioscience and medical technology industry, with nearly 100 member companies and universities across the state, including Fortune 500 corporations. Prior to founding MedTech, she served as Senior Consultant at the San Francisco headquarters of Edgar, Dunn & Company, an international management consultancy specializing in strategic planning for the financial services industry. Ms. Erickson received a B.S. in Molecular, Cellular and Developmental Biology from Yale University.

Sandy Macrae, M.B., Ch.B., Ph.D.

Sandy Macrae, M.B., Ch.B., Ph.D.

President and CEO

Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr. Macrae received his B.Sc. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.

Duncan McKay

Duncan McKay

Vice President Europe and General Manager

R. Andrew Ramelmeier, Ph.D.

R. Andrew Ramelmeier, Ph.D.

Senior Vice President and Chief Manufacturing & Quality Officer

Edward Rebar, Ph.D.

Edward Rebar, Ph.D.

Senior Vice President and Chief Technology Officer

Dr. Rebar joined Sangamo in 1998, and over the last 20 years he has led the development of the Company's zinc finger protein platform. He has authored over 60 publications relating to the development of customized DNA binding proteins and nucleases for genome editing.  Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley.  Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.

McDavid Stilwell

McDavid Stilwell

Vice President, Corporate Communications and Investor Relations

McDavid Stilwell has served as Vice President, Corporate Communications and Investor Relations since November 2016.  He has over 20 years of relevant experience across various business functions, including communications, investor relations, business development and financial analysis. Prior to joining Sangamo, Mr. Stilwell served as Vice President, Corporate Communications, Investor Relations & Business Development at Orexigen Therapeutics, Inc. From 2005 to 2012 he served as Director, Business Development, Corporate Communications and Financial Analysis at GTx, Inc., a development stage biopharmaceutical company. Earlier, Mr. Stilwell worked for five years as a Senior Investment Analyst for Shadwell Capital LLC, a hedge fund. Mr. Stilwell began his career as a journalist, first as a newspaper reporter and later as an executive editor of an investor newsletter covering financial services industry mergers and acquisitions. Mr. Stilwell received a B.A. in Liberal Arts from St. John’s College, Annapolis, Maryland, and a M.B.A. from Harvard Business School.

Heather Turner, J.D.

Heather Turner, J.D.

Senior Vice President and General Counsel

Ms. Turner has over 18 years of experience advising public and private life science companies on various matters, including corporate governance, compliance, reporting, public reporting, public offering, mergers and acquisitions, and commercial, manufacturing and development contracts. Ms. Turner joins Sangamo from Atara Biotherapeutics, Inc., which she joined in 2015 and where she served as executive vice president, general counsel and secretary, and also, most recently, as head of portfolio strategy. From 2007 to 2015, she served as General Counsel and Secretary at Orexigen Therapeutics, Inc., where she led various general and administrative functions including compliance, risk management, legal, human resources and facilities. Earlier in her career, she worked as an associate in the corporate securities group at Cooley LLP.

Ms. Turner holds a J.D. from the University of California Los Angeles School of Law and is a member of the State Bar of California.

Kathy Yi

Kathy Yi

Senior Vice President and CFO

Kathy Yi has served as Senior Vice President and Chief Financial Officer since March 2017. Ms. Yi was formerly with Novartis Pharmaceuticals where she served as Head of Finance, Inhalation Technical Research & Development, responsible for the financial management of technical R&D organizations in California and Switzerland. Prior to joining Novartis, she was with Life Technologies Corp. from 2007 to 2014, during which time she held financial management positions of increasing seniority, including Finance Leader, Corporate FP&A. Prior to joining Life Technologies, Ms. Yi held various positions in finance at Intel Corp., from 2001 to 2007. She began her career as a Process/Project Engineer at Bechtel Corp., a leading global engineering, construction and project management company. Ms. Yi received a B.S. degree in Chemical Engineering from the University of California at Berkeley and an M.B.A. degree from Columbia Business School.

Sign Up For E-Mail Alerts

Sign Up